

Biosafety Clearing-House (BCH)

LIVING MODIFIED ORGANISM (LMO)


BCH-LMO-SCBD-109735-1

[? Decisions on the LMO ? Risk Assessments](#)

LAST UPDATED: 25 FEB 2016

Living Modified Organism identity


The image below identifies the LMO through its unique identifier, trade name and a link to this page of the BCH. Click on it to download a larger image on your computer. For help on how to use it go to the LMO quick-links page.



VAXXITEK® HVT+ IBD

CBD

<https://bch.cbd.int/database/record?documentID=109735>



Read barcode or type above URL into internet browser to access information on this LMO in the Biosafety Clearing-House © SCBD 2012

Name

VAXXITEK® HVT+ IBD

EN

Transformation event

vHTV013-69

Developer(s)

- **PERSON:** DRA LUCIANA FERNANDA MATIAS SOARES | [BCH-CON-SCBD-109734-2](#)

PERSON

Dra Luciana Fernanda Matias Soares
President of Internal Biosafety Commission, Animal Health
Fazenda São Francisco s/nº - Caixa Postal: 242 - PAULÍNIA (SP)
Paulínia, São Paulo
13140970, Brazil
Phone: +55 19 3874-8601
Fax: +55 19 3874-8080
Email: luciana.soares@merial.com.br
Website: <http://www.merial.com.br>

RELATED ORGANIZATION

Description

Vaxxitek HVT + IBD is a live vaccine based on the use of a recombinant turkey Herpesvirus (HVT) expressing the VP2 gene of the Infectious Bursal Disease (Gumboro disease) Virus (IBDV).

EN

This vaccine contains a live strain of serotype 3 vectored virus that has been shown to aid in the prevention of Bursal disease and Marek's disease.

Recipient Organism or Parental Organisms

The term "Recipient organism" refers to an organism (either already modified or non-modified) that was subjected to genetic modification, whereas "Parental organisms" refers to those that were involved in cross breeding or cell fusion.

[BCH-ORGA-SCBD-105225-3](#) ORGANISM | MELEAGRID ALPHAHERPESVIRUS 1 (TURKEY HERPESVIRUS, MELEAGRID HERPESVIRUS 1) |

Viruses

Point of collection or acquisition of the recipient organism or parental organisms

Meleagrid herpesvirus 1 (HVT) strain: FC-126

EN

Related LMO(s)

[BCH-LMO-SCBD-105260-1](#) | VECTORMUNE® HVT-IBD | Dr Alexis Henry Gaetan Goux Production of medical or pharmaceutical compounds (human or animal) - Vaccines

Characteristics of the modification process

Vector

vHVT013-69

EN

Techniques used for the modification

Other (Homologous Recombination)

Introduced or modified genetic element(s)

Some of these genetic elements may be present as fragments or truncated forms. Please see notes below, where applicable.

[BCH-GENE-SCBD-105223-1](#) VIRAL PROTEIN 2 GENE | (GUMBORO VIRUS) |

Protein coding sequence | Production of medical or pharmaceutical compounds (human or animal) (Vaccines)

Notes regarding the genetic elements present in this LMO

Vaxxitek HVT + IBD vaccine is a live recombinant vaccine against Gumboro disease (or infectious bursal disease) and Marek's disease in chickens. It is a frozen vaccine to be diluted with an aqueous diluent. The active ingredient is the production-cell associated vHVT013-69 virus vaccine strain, a recombinant turkey Herpesvirus (HVT) expressing the VP2 coding sequence of Infectious Bursal Disease Virus (IBDV). The parental strain of Vaxxitek HVT + IBD (named FC-126) belongs to the serotype 3 of Marek's disease and is widely used in classical vaccination against Marek's disease. HVT strains are apathogenic in all species, and do not replicate in mammalian cells. The inserted sequence corresponds to the sequence coding for the VP2 protein of Infectious Bursal Disease Virus (IBDV). It has been cloned from 52/70 Faragher strain. The VP2 protein is the only protein of IBDV that induces protection against Gumboro disease.

EN

LMO characteristics

Modified traits

Production of medical or pharmaceutical compounds (human or animal)
Vaccines

Common use(s) of the LMO

Vaccine

Additional Information

Other relevant website addresses and/or attached documents

? [Vaxxitek HVT + IBD - Merial \(English \)](#)
? [VAXXITEK® HVT+ IBD - Merial \(English \)](#)

[BCH-LMO-SCBD-109735-1](#)

Further Information

Questions about the Cartagena Protocol on Biosafety or the operation of the Biosafety Clearing-House may be directed to the Secretariat of the Convention on Biological Diversity.

Secretariat of the Convention on Biological Diversity

413 rue Saint-Jacques, suite 800

Montreal, Québec, H2Y 1N9

Canada

Fax: +1 514 288-6588

Email: secretariat@cbd.int